WallStreetZenWallStreetZen

NASDAQ: MGNX
Macrogenics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for MGNX

Based on 3 analysts offering 12 month price targets for Macrogenics Inc

Min Forecast
$2.00+33.33%
Avg Forecast
$2.67+77.8%
Max Forecast
$3.00+100%

Should I buy or sell MGNX stock?

Based on 3 analysts offering ratings for Macrogenics Inc.

Buy
Strong Buy
1 analysts 33.33%
Buy
0 analysts 0%
Hold
2 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although MGNX's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates MGNX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their MGNX stock forecasts and price targets.

MGNX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-03
lockedlocked$00.00+00.00%2025-09-17
lockedlocked$00.00+00.00%2025-08-15
lockedlocked$00.00+00.00%2025-05-20

1 of 1

Forecast return on equity

Is MGNX forecast to generate an efficient return?

Company
N/A
Industry
281.93%
Market
232.29%

Forecast return on assets

Is MGNX forecast to generate an efficient return on assets?

Company
N/A
Industry
96.39%

MGNX earnings per share forecast

What is MGNX's earnings per share in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
-$2.03
Avg 2 year Forecast
-$1.66
Avg 3 year Forecast
-$2.05

MGNX revenue forecast

What is MGNX's revenue in the next 3 years based on estimates from 9 analysts?

Avg 1 year Forecast
$71.4M-44.03%
Avg 2 year Forecast
$45.4M-64.41%
Avg 3 year Forecast
$34.6M-72.93%
MGNX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

MGNX revenue growth forecast

How is MGNX forecast to perform vs Biotechnology companies and vs the US market?

Company
-37.4%
Industry
104.98%
Market
25.7%
MGNX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
MGNX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

MGNX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MGNX$1.50$2.67+77.80%Buy
SLGL$34.00$50.00+47.06%Buy
ADVM$4.29$16.60+286.95%Buy
ORMP$2.33N/AN/A
PRLD$1.52$4.00+163.16%Buy
View Top Biotech Stocks

Macrogenics Stock Forecast FAQ

Is Macrogenics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: MGNX) stock is to Buy MGNX stock.

Out of 3 analysts, 1 (33.33%) are recommending MGNX as a Strong Buy, 0 (0%) are recommending MGNX as a Buy, 2 (66.67%) are recommending MGNX as a Hold, 0 (0%) are recommending MGNX as a Sell, and 0 (0%) are recommending MGNX as a Strong Sell.

If you're new to stock investing, here's how to buy Macrogenics stock.

What is MGNX's earnings growth forecast for 2025-2027?

(NASDAQ: MGNX) Macrogenics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 48.02%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.33%.

Macrogenics's earnings in 2025 is -$75,886,000.On average, 9 Wall Street analysts forecast MGNX's earnings for 2025 to be -$128,661,528, with the lowest MGNX earnings forecast at -$167,382,076, and the highest MGNX earnings forecast at -$90,997,398. On average, 8 Wall Street analysts forecast MGNX's earnings for 2026 to be -$104,888,972, with the lowest MGNX earnings forecast at -$179,780,748, and the highest MGNX earnings forecast at -$16,605,365.

In 2027, MGNX is forecast to generate -$129,477,563 in earnings, with the lowest earnings forecast at -$195,279,088 and the highest earnings forecast at -$51,144,523.

What is MGNX's revenue growth forecast for 2025-2027?

(NASDAQ: MGNX) Macrogenics's forecast annual revenue growth rate of -37.4% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.7%.

Macrogenics's revenue in 2025 is $127,625,000.On average, 9 Wall Street analysts forecast MGNX's revenue for 2025 to be $4,518,303,907, with the lowest MGNX revenue forecast at $3,372,438,858, and the highest MGNX revenue forecast at $6,502,977,090. On average, 8 Wall Street analysts forecast MGNX's revenue for 2026 to be $2,872,949,489, with the lowest MGNX revenue forecast at $0, and the highest MGNX revenue forecast at $7,114,054,509.

In 2027, MGNX is forecast to generate $2,185,772,056 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $3,985,287,516.

What is MGNX's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: MGNX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 96.39%.

What is MGNX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year MGNX price target, the average MGNX price target is $2.67, with the highest MGNX stock price forecast at $3.00 and the lowest MGNX stock price forecast at $2.00.

On average, Wall Street analysts predict that Macrogenics's share price could reach $2.67 by Nov 3, 2026. The average Macrogenics stock price prediction forecasts a potential upside of 77.8% from the current MGNX share price of $1.50.

What is MGNX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: MGNX) Macrogenics's current Earnings Per Share (EPS) is -$1.20. On average, analysts forecast that MGNX's EPS will be -$2.03 for 2025, with the lowest EPS forecast at -$2.65, and the highest EPS forecast at -$1.44. On average, analysts forecast that MGNX's EPS will be -$1.66 for 2026, with the lowest EPS forecast at -$2.84, and the highest EPS forecast at -$0.26. In 2027, MGNX's EPS is forecast to hit -$2.05 (min: -$3.09, max: -$0.81).

What is MGNX's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: MGNX) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.